Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, SVY

ESO Launches 2018 ESO EMS Index to Track Nationwide EMS Performance Across Five Metrics


AUSTIN, Texas, Feb. 15, 2018 /PRNewswire/ -- ESO Solutions, Inc., the leading data and software company serving emergency medical services (EMS), hospitals and fire departments, today announced the findings of its inaugural report, the 2018 ESO EMS Index. The Index tracks performance of EMS agencies nationwide across five metrics: Stroke assessment and documentation, overdose events, end-tidal carbon dioxide (ETCO2) monitoring, 12-lead electrocardiogram (EKG) use and aspirin administration for chest pain. Data used for the Index are from January 1, 2017 through December 31, 2017.   

ESO Solutions, Inc. Logo (PRNewsfoto/ESO Solutions, Inc.)

"There are changes on the horizon for EMS agencies across the country," said Dr. Brent Myers, Chief Medical Officer for ESO. "In particular, we are seeing new data and research emerge around the increased importance of stroke assessment and documentation that could improve patient outcomes. Additionally, the opioid crisis continues to be an issue that will have an effect on EMS providers. This newly launched Index is part of our ongoing commitment to the smart use of data to help agencies across the country assess their performance across a handful of metrics." 

Key Findings Include: 

The full Index can be downloaded here.

About the Index
The dataset for the ESO EMS Index is real-world data, compiled and aggregated from more than 1,000 agencies across the United States that use ESO's products and services. These data are based on 5.02 million patient encounters between January 1, 2017 and December 31, 2017, representing a full calendar year.

About ESO Solutions
ESO Solutions, Inc., is dedicated to improving community health and safety through the power of data. Since its founding in 2004, the company has been a pioneer in electronic patient care records (ePCR) software for emergency medical services, fire departments and ambulance services. Today, ESO serves more than 13,000 agencies throughout the U.S. The company's healthcare, public safety and technology experts deliver the most innovative software and data solutions on the market, including the industry-leading ESO Electronic Health Record (EHR)ESO Health Data Exchange (HDE), the first-of-its-kind healthcare interoperability platform; record management system (RMS) for fire departments; and ambulance revenue recovery/billing software. ESO is also playing a leading role in helping EMS provider organizations across the nation successfully transition to NEMSIS Version 3 and new state standards for electronic patient care reporting. 

ESO is headquartered in Austin, Texas. For more information, visit www.esosolutions.com.

 

SOURCE ESO Solutions, Inc.


These press releases may also interest you

at 10:52
Doctor's Best Inc., a leading nutritional supplement company, announced today their launch of two new products, Glutathione + Milk Thistle with Setria® and Boswellia + UC-II®....

at 10:50
Novocure today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held...

at 10:45
In observance of Parkinson's Disease Awareness Month, Quest Research Institute (Quest), a site within Alcanza Clinical Research's network located in Detroit, emphasizes the importance of raising awareness about Parkinson's disease (PD), recognizing...

at 10:31
Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated...

at 10:30
Vaccines Market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029 according to a new report by MarketsandMarketstm. Similarly, the vaccines...

at 10:25
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that updated Phase 1/2 data for AU-007 will be presented at the American Society...



News published on and distributed by: